Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

Exclusion Criteria

• •1. Treatment for TTP within the past 2 months
• •2. Severe active infection indicated by sepsis (requirement for pressors with or without positive blood cultures) or clinical evidence of enteric infection with E. coli O157:H7 or related organism
• •3. Currently under treatment for cancer (subjects with localized skin carcinoma will be accepted)
• •4. Microangiopathic hemolytic anemia due to a mechanical heart valve
• •5. Severe hypertension, as defined by systolic BP \>180 AND diastolic BP \>120, or papilledema
• •6. Organ or stem cell transplant
• •7. Use of calcineurin inhibitors (sirolimus, tacrolimus, cyclosporin A) within 6 months prior to diagnosis of TTP
• •8. Disseminated intravascular coagulation as defined by:
• •a. INR \>2.0 (unrelated to anticoagulation, unresponsive to Vitamin K) or b. Fibrinogen \<100 mg/dl
• •9. Pregnancy
• •10. Known congenital TTP.
• •11. Rituximab within the previous year.
• •12. HIV history or positive serology
• •13. History of hepatitis B or positive serology for HBsAg or Anti-HBc
• •14. Persistent or unexplained platelet count below 150,000/μL within 3 months of current TTP presentation
• •15. Hypersensitivities or allergies to murine and/or humanized antibodies
• •16. Current participation in trials of investigational therapies or devices, other than central catheters